Summarized Financial Data (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Oragenics, Inc.
Schedule of Equity Method Investments [Line Items]
Revenues	$ 215	$ 176
Gross profit	135	112
Loss from operations	(1,649)	(1,736)
Net loss	(1,641)	(1,590)
Ziopharm Oncology, Inc.
Schedule of Equity Method Investments [Line Items]
Revenues	200	200
Operating expenses	9,984	23,783
Loss from operations	(9,784)	(23,583)
Other	73	10,784
Net loss	$ (9,711)	$ (12,799)